Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03719170 · ClinicalTrials.gov registry record · NA
Evaluation of the National Randomized Proton Pump Inhibitor De-prescribing (RaPPID) Program
A NA study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- NA
- Development phase
- 220,306
- Enrollment target
NCT03719170: Completed NA study, sponsored by VA Office of Research and Development.
NCT03719170 is a NA study that has completed, run by VA Office of Research and Development. The registered enrollment target is 220,306 participants, above the 1,400-participant average among 58,714 other NA trials with a reported enrollment target (15636% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03719170, a NA study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- NA
- Development phase
- 220,306 participants
- Enrollment target
Study Summary
Proton pump inhibitors (PPIs) are medications used to treat acid-related stomach disorders, such as chronic heartburn. These medications are widely used by Veterans, with over 11 million 30-day prescriptions being filled each year. Though they are highly effective, long-term use of PPIs may be harmful. For this reason, experts recommend that PPIs be stopped in patients who do not have a clear need for these medications. Unfortunately, PPIs continue to be overused. To address this issue, the VA is implementing a national program to de-prescribe (i.e., reduce the dose of, or stop) PPIs. In this study, the investigators will be evaluating this national program by assessing: (a) how successfully the program was implemented; (b) understanding how effective the program was in improving appropriate use of PPIs; and, (c) ensuring no unintended consequences (such as peptic ulcer bleeding) occurred with PPI de-prescribing. This study addresses a potential safety concern for Veterans and aligns with VA's broader goal of de-implementing low-value care.
Primary Outcome
The proportion of days proton pump inhibitors are prescribed in the 12 months following the index visit.
Interventions
- BEHAVIORAL PPI De-prescribing Program
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220,306 participants |
| Start Date | 2019-09-16 |
| Est. Completion | 2021-11-30 |
| Phase | NA |
What the finished NCT03719170 record still lists
NCT03719170 is an interventional study that assigns participants to a tested intervention. Its 220,306 participants enrollment target places it among the larger protocols in the corpus, above the 1,400-participant average among 58,714 other NA trials with a reported enrollment target (15636% higher).
The record links to 0 conditions, and to 1 intervention - of which PPI De-prescribing Program is the first listed.
NCT03719170 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03719170 about?
NCT03719170 is a clinical study titled "Evaluation of the National Randomized Proton Pump Inhibitor De-prescribing (RaPPID) Program". Proton pump inhibitors (PPIs) are medications used to treat acid-related stomach disorders, such as chronic heartburn. These medications are widely used by Veterans, with over 11 million 30-day prescriptions being filled each year. Though they are highly effective, long-term use of PPIs may be harmf...
What is the current status of trial NCT03719170?
This trial is currently completed. It is a NA study. The enrollment target is 220,306 participants. The study started on 2019-09-16. Estimated completion is 2021-11-30.
What interventions are being tested in trial NCT03719170?
The interventions under investigation include: PPI De-prescribing Program (BEHAVIORAL).
Who is sponsoring clinical trial NCT03719170?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03719170's enrollment target sits among peer trials
220,306 1st of 2000 higher than 2,000 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04735835 · 250,000 participants · NA
Personalized Responses to Dietary Composition Trial 3
- NCT06090578 · 180,000 participants · NA
TabCAT Brain Health Assessment in Primary Care
- NCT06917339 · 156,000 participants
Retrospective Analyses of TrakStar Database
- NCT06232551 · 152,000 participants · NA
Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI